Hanmi registers Phase 3 trial of HIP2602 in erectile dysfunction
The study, led by Hanmi Pharmaceutical Company Limited, plans to enroll 225 participants and begin in October 2026. It is a multicenter, randomized, double-blind Phase III trial evaluating the efficacy and safety of HIP2602 in erectile dysfunction patients.
Primary source
ClinicalTrials.gov registry record, October 27, 2026
A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
Read the source: A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation